Browsing Category

24460 posts

CARsgen Announces Data of Allogeneic BCMA CAR-T Cell Therapy CT0596 for Relapsed/Refractory Multiple Myeloma at the 2025 ASH Annual Meeting

SHANGHAI, Dec. 8, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code:…
RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION

RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION

SINGAPORE, Dec. 8, 2025 /PRNewswire/ — AI/ML health-tech startup Respiree has received approval…

AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore

SINGAPORE, Dec. 8, 2025 /PRNewswire/ — ChemLex, a next-generation AI-for-science company, today…

ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed

MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX:…
The 4th China International Supply Chain Expo Set for Beijing in June 2026

The 4th China International Supply Chain Expo Set for Beijing in June 2026

Sustained Worldwide Outreach Drives Greater Collaboration Opportunities BEIJING, Dec. 7, 2025 /PRNewswire/…
How is Thailand addressing health risks from smog?

How is Thailand addressing health risks from smog?

Thailand is implementing a multi-faceted response to health risks from smog, especially…
CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue

CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue

SHANGHAI, Dec. 7, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code:…

All Approved Indications of Five Akeso's Innovative Drugs Included in China's Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs

HONG KONG, Dec. 7, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) ("Akeso" or…